Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Takashi KojimaManish A ShahKei MuroEric FrancoisAntoine AdenisChih-Hung HsuToshihiko DoiToshikazu MoriwakiSung-Bae KimSe-Hoon LeeJaafar BennounaKen KatoLin ShenPeter EnzingerShu-Kui QinPaula FerreiraJia ChenGustavo C GirottoChristelle De La FouchardièreHelene SenellartRaed Al-RajabiFlorian LordickRuixue WangShailaja SuryawanshiPooja BhagiaS Peter KangJean-Philippe Metgesnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Pembrolizumab prolonged OS versus chemotherapy as second-line therapy for advanced esophageal cancer in patients with PD-L1 CPS ≥ 10, with fewer treatment-related adverse events.